NASDAQ: LXRXLexicon Pharmaceuticals Inc Stock
$2.00+0.32 (+19.05%)
Updated May 8, 2026
LXRX Price
$2.00
Fair Value Price
N/A
Market Cap
$888.39M
52 Week Low
$0.51
52 Week High
$2.00
P/E
-28.57x
P/B
4.38x
P/S
8.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$69.64M
Earnings
-$26.09M
Gross Margin
99.5%
Operating Margin
-25.84%
Profit Margin
-37.5%
Debt to Equity
0.33
Operating Cash Flow
-$39M
Beta
1.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LXRX Overview
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LXRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LXRX
Ranked#168 of 458
Ranked#168 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.79 | A | |
| $48.16 | A | |
| $7.49 | A |
Be the first to know about important LXRX news, forecast changes, insider trades & much more!
LXRX News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LXRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LXRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LXRX is good value based on its book value relative to its share price (4.38x), compared to the US Biotechnology industry average (4.99x)
P/B vs Industry Valuation
LXRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LXRX due diligence checks available for Premium users.
Valuation
LXRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-28.57x
Industry
16.13x
Market
23.07x
LXRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.38x
Industry
4.99x
LXRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LXRX's financial health
Profit margin
Revenue
$21.1M
Net Income
-$1.0M
Profit Margin
-4.9%
LXRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LXRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$268.8M
Liabilities
$66.0M
Debt to equity
0.33
LXRX's short-term assets ($186.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LXRX's short-term assets ($186.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LXRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LXRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.7M
Investing
-$70.3M
Financing
$88.8M
LXRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LXRX vs Biotech Stocks
Lexicon Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.